Axatilimab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Axatilimab. Educational only — not medical advice.
Labeled uses
NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
Source: FDA labeling via NIH DailyMed (set bb6dba23…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.